Exelixis, Inc. (EXEL) — Stock Valuation & Research

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several…

EXEL key statistics

Explore EXEL's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.